Inflammatory Bowel Disease (IBD) is a chronic condition of the bowel affecting over 1.5 million people in the United States.
The recurrent nature of IBD makes affected patients ideal candidates for electronic patient reported outcome (e-PRO) monitoring that centers on enhanced symptom tracking and improved communication with care teams. HealthPROMISE is a prescribed mobile application that assesses the impact of e-PROs on improving patients’ quality of life (QoL).
At baseline, patients in the intervention arm reported a mean quality of life score of 30.3 ± 11.3. The last available follow-up QoL scores showed improvement among patients using HealthPROMISE to 25.3 ± 11.3 (p < 0.001). Patients engaging with HealthPROMISE reported more equitable participation in their care decision-making process, and showed improved health outcomes compared to patients not using HealthPROMISE.
In the study, 162 were randomized
to the intervention group. 158 were randomized to the control group.
Quality of Care
Leads to positive health outcomes
as well as improvement in QoL
Who continue to frequently log into HealthPROMISE app and update their e-PROs.